Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/0AkjkBpsX4
Ok this is fascinating !! #Teprotumumab is a fully human monoclonal antibody that targets the insulin-like growth factor 1 (IGF-1) receptor (IGF-1R). It was approved by the FDA in January 2020 for the treatment of thyroid eye disease. https://t.co/lS7A8E1
Spring of 2017 the study readout and was unblinded. The results were unambiguous and remarkable and ended up being published in NEJM https://t.co/AeAFSJQhyx
RT @tomatom01987693: 私が長らく応援してるニッチながらビックなテプロツムマブ(抗IGF-1受容体阻害抗体). 甲状腺眼症に対するテプロツムマブの第3相試験. 眼球突出に対し解析症例の全例に改善を認めた. NNTは1.36. (N Engl J Med 2…
Patients with Thyroid Eye Disease often become extremely self conscious about their bulging reddened eyes, so a new drug called #Tepezza which contains #teprotumumab and which has just been approved in the USA is very good news
👣📚📚✏ **Teprotumumab*👀** for the TREATMENT of ACTIVE THYROID EYE👀 DISEASE👀 | NEJM⛄🎄🦉👣 🐧 https://t.co/6qZZPrd8Jx
Data on this drug in Graves ophthalmopathy from @NEJM https://t.co/XhDIAGt6v3 https://t.co/DvI0hNcmbH https://t.co/7daEX5b2IU
Teprotumumab for the Treatment of Active Thyroid Eye Disease - https://t.co/oj1z87YYw2 https://t.co/CzeOcCwCcQ
Första året på marknaden nu guidance >$650m i sales, upp från tidigare >$200m och nu peak sales >$3bn, upp från tidigare >$1bn. Bra innovation ger ofta kommersiell framgång. $HZNP
RT @RaymonGrogan: Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/dTw0nZo8TW FDA approves first treatment…
RT @dathonva: @charlesvallej15 In January 2020, FDA also approved teprotumumab for TED https://t.co/POFraMSz5S
@charlesvallej15 In January 2020, FDA also approved teprotumumab for TED https://t.co/POFraMSz5S
@charlesvallej15 @RosenelliEM Thank you Charles for bringing attention to an important topic in the management of Graves’ disease! Earlier this year teprotumumab, an IGF-1 receptor inhibitor, was approved by the FDA. It is very new and I haven’t used in an
Första kvartalet på marknaden, och $HZNP höjer prognosen för tepros (Tepezza) försäljning 2020 från $30-40m, till "at least $200m". Bra science leder ofta till bra kommersialisering. Peak sales på $1bn ändras nu till $1bn+.
RT @SeenTiro: Teprotumumab, un nuevo fármaco para la orbitopatia de Graves. Resultados de un ensayo clínico publicado en el New England Jou…
Teprotumumab (Tapezza) for thyroid eye disease: recent FDA approval. IGF-I receptor inhibitor IV infusion q 3 weeks for 21 weeks Improved clinically important outcomes #endotwitter Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM http
👀 TEPROTUMUMAB PARA EL TRATAMIENTO DE LA ENFERMEDAD ACTIVA DEL OJO TIROIDEO 🔎 Engl J Med https://t.co/lyxkgTnc44 💥CONOCE NUESTROS Libros, eBooks y Cursos100% On Line ✔️ [email protected]">@gmail.com">[email protected] ✔️ WhatsApp +584242994175 / +58412 https://t.co/
RT @rubon_MGGD: 甲状腺眼症の新しい治療薬 「テプロツムマブ」 特に中度~重度の活動期に効果があるようなので期待したいです
甲状腺眼症の新しい治療薬 「テプロツムマブ」 特に中度~重度の活動期に効果があるようなので期待したいです
RT @RaymonGrogan: Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/dTw0nZo8TW FDA approves first treatment…
RT @RaymonGrogan: Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/dTw0nZo8TW FDA approves first treatment…
Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/dTw0nZo8TW FDA approves first treatment for thyroid eye disease https://t.co/idrf4ijgnP @TheAAES @AmThyroidAssn @TheAACE @GDATF @jsuliburk
RT @Fajehani: I picked this great article for @MUSChealth Endocrinology journal club this week. (Teprotumumab for the Treatment of Active…
I picked this great article for @MUSChealth Endocrinology journal club this week. (Teprotumumab for the Treatment of Active Thyroid Eye Disease). #endotwitter #medtwitter #MedEd #endocrinology #VisualAbstract @NEJM @NEJMres360 https://t.co/TqJa3bLnPS htt
RT @NatureRevEndo: Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/EjLRJuU1Vy
RT @RosaCasan: Teprotumumab mejora la proptosis en más del 80% de los pacientes con oftalmopatia distiroidea, una media de 2.8 mm, y con di…
Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/VCJyPI6yIx 【日本語ver.】https://t.co/e9sZayh2Hp 活動期甲状腺眼症に対するテプロツムマブ。 日本でも早く承認されると良いですね。
Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/iDNgJFwXdI
RT @tomatom01987693: 私が長らく応援してるニッチながらビックなテプロツムマブ(抗IGF-1受容体阻害抗体). 甲状腺眼症に対するテプロツムマブの第3相試験. 眼球突出に対し解析症例の全例に改善を認めた. NNTは1.36. (N Engl J Med 2…
En una época donde los ac. monoclonales han cambiado la medicina, otra alternativa en el tx de orbitopatia tiroidea que hasta ahorita ha sido tratada muchas veces sin éxito, me preguntó cuoa será el costo, supongo que inaccesible como las mayor parte de lo
RT @NatureRevEndo: Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/EjLRJuU1Vy
RT @CambridgeNeuro1: For all those alemtuzumab users! Thyroid eye disease responds to an anti-IGF1 receptor antibody: teprotumumab https:…
For all those alemtuzumab users! Thyroid eye disease responds to an anti-IGF1 receptor antibody: teprotumumab https://t.co/KEaFdHSD5a
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NatureRevEndo: Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/EjLRJuU1Vy
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @tomatom01987693: 私が長らく応援してるニッチながらビックなテプロツムマブ(抗IGF-1受容体阻害抗体). 甲状腺眼症に対するテプロツムマブの第3相試験. 眼球突出に対し解析症例の全例に改善を認めた. NNTは1.36. (N Engl J Med 2…
RT @tomatom01987693: 私が長らく応援してるニッチながらビックなテプロツムマブ(抗IGF-1受容体阻害抗体). 甲状腺眼症に対するテプロツムマブの第3相試験. 眼球突出に対し解析症例の全例に改善を認めた. NNTは1.36. (N Engl J Med 2…
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @tomatom01987693: 私が長らく応援してるニッチながらビックなテプロツムマブ(抗IGF-1受容体阻害抗体). 甲状腺眼症に対するテプロツムマブの第3相試験. 眼球突出に対し解析症例の全例に改善を認めた. NNTは1.36. (N Engl J Med 2…
私が長らく応援してるニッチながらビックなテプロツムマブ(抗IGF-1受容体阻害抗体). 甲状腺眼症に対するテプロツムマブの第3相試験. 眼球突出に対し解析症例の全例に改善を認めた. NNTは1.36. (N Engl J Med 2020; 382: 341-352) https://t.co/MITV9MKcan https://t.co/DWRUUmaZp4
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
#NEJM Chez les patients atteints de pathologie de l’œil d’origine thyroïdienne, le #teprotumumab a eu pour résultat une meilleure gestion de la proptose, de la diplopie, un meilleur score d’activité clinique, et une meilleure qualité de vie versus placebo
RT @NatureRevEndo: Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/EjLRJuU1Vy
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @SeenTiro: Teprotumumab, un nuevo fármaco para la orbitopatia de Graves. Resultados de un ensayo clínico publicado en el New England Jou…
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NatureRevEndo: Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/EjLRJuU1Vy
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
I must have this.
Interesting and timely
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NEJM: Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
Original Article: Teprotumumab for the Treatment of Active Thyroid Eye Disease https://t.co/oIJjHs7dQx
RT @NatureRevEndo: Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/EjLRJuU1Vy
RT @NatureRevEndo: Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/EjLRJuU1Vy
RT @NatureRevEndo: Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/EjLRJuU1Vy
Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/EjLRJuU1Vy
For the first time in 3 years my doctor told me, “there’s a treatment available.” Did I cry? Almost, but they would’ve been happy tears for once! #thyroideyedisease #graves https://t.co/S28GP54973
RT @NEJM: Strong evidence has implicated the insulin-like growth factor I receptor (IGF-IR) in the pathogenesis of thyroid eye disease. htt…
RT @SeenTiro: Teprotumumab, un nuevo fármaco para la orbitopatia de Graves. Resultados de un ensayo clínico publicado en el New England Jou…
甲狀腺眼凸者的福音 https://t.co/a4Xg8uZI8R
Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/EaShYSJwTz
It is such an exciting time to be an immunologist! I suspect (based on no data whatsoever) that teprotumumab will go on to be used for other uses aside from Thyroid eye disease. https://t.co/nwR1WBqscl
RT @SeenTiro: Teprotumumab, un nuevo fármaco para la orbitopatia de Graves. Resultados de un ensayo clínico publicado en el New England Jou…
RT @AmpudiaBlasco: @isidoro_cano @Medscape Following the previous tweet of Dr. Isidoro Cano, I attached a support trial just published toda…
RT @SeenTiro: Teprotumumab, un nuevo fármaco para la orbitopatia de Graves. Resultados de un ensayo clínico publicado en el New England Jou…
RT @SeenTiro: Teprotumumab, un nuevo fármaco para la orbitopatia de Graves. Resultados de un ensayo clínico publicado en el New England Jou…
RT @florencarral: Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/VWjGOdagHU
Teprotumumab for the Treatment of Active Thyroid Eye Disease. https://t.co/rhS7d1uYdm
RT @SeenTiro: Teprotumumab, un nuevo fármaco para la orbitopatia de Graves. Resultados de un ensayo clínico publicado en el New England Jou…
RT @NEJM: Strong evidence has implicated the insulin-like growth factor I receptor (IGF-IR) in the pathogenesis of thyroid eye disease. htt…
RT @SeenTiro: Teprotumumab, un nuevo fármaco para la orbitopatia de Graves. Resultados de un ensayo clínico publicado en el New England Jou…
RT @SeenTiro: Teprotumumab, un nuevo fármaco para la orbitopatia de Graves. Resultados de un ensayo clínico publicado en el New England Jou…
Teprotumumab, un nuevo fármaco para la orbitopatia de Graves. Resultados de un ensayo clínico publicado en el New England Journal of Medicine. https://t.co/TlkmGnMzi0
RT @florencarral: Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/VWjGOdagHU
RT @florencarral: Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/VWjGOdagHU
RT @NEJM: Strong evidence has implicated the insulin-like growth factor I receptor (IGF-IR) in the pathogenesis of thyroid eye disease. htt…
New NNT→Teprotumumab for the Treatment of Active Thyroid Eye Disease. https://t.co/t4exvRZjnT
RT @AntmijAntonio: En los pacientes con oftalmopatía tiroidea, el teprotumumab produjo mejores resultados con respecto a la proptosis, la p…
RT @NEJM: Strong evidence has implicated the insulin-like growth factor I receptor (IGF-IR) in the pathogenesis of thyroid eye disease. htt…
RT @AmpudiaBlasco: @isidoro_cano @Medscape Following the previous tweet of Dr. Isidoro Cano, I attached a support trial just published toda…
Teprotumumab for the Treatment of Active Thyroid Eye Disease | NEJM https://t.co/PDhtw7CNRw